Advertisement
Advertisement

ARWR

ARWR logo

Arrowhead Research Corporation

76.67
USD
Sponsored
-3.02
-3.79%
May 15, 15:59 UTC -4
Closed
exchange

After-Market

76.56

-0.11
-0.14%

Arrowhead Research Corporation Profile

About

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Info & Links

CEO

Christopher Anzalone

Headquarters

177 E. Colorado Blvd, Suite 700
Pasadena, CA 91105, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.arrowheadpharma.com

Auditor

KPMG LLP

Share holders

86

Employees

711

Arrowhead Research Corporation Statistics

Valuation Measures

Market Capitalization2

10.78B

Enterprise Value

10.79B

Enterprise Value/EBITDA(ttm)

33.72

Price to Earnings Ratio(ttm)

43.29

Price to Sales(ttm)

8.50

Price to Book(mrq)

16.48

Price to Cash(ytd)

554.69

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

18.54%

Profit Margin(ttm)

-140.11%

Return on Equity(ttm)

35.64%

Return on Invested Capital(ttm)

22.51%

Return on Assets(ttm)

13.61%

Income Statement

Revenue(ttm)

1.09B

Revenue Per Share(ttm)

7.79

Gross Profit(ttm)

1.09B

EBITDA(ttm)3

319.86M

Net Income Available to Common(ttm)

202.26M

Diluted EPS(ttm)

1.53

Share Statistics

Beta (5Y Monthly)

1.26

52-Week Change

399.80%

S&P 500 52-Week Change

24.23%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

140.03M

Dividend Yield

0.00%

Float4

134.99M

% Held by Insiders

3.60%

% Held by Institutions

62.61%

Balance Sheet

Total Cash(mrq)

916.61M

Total Cash Per Share(mrq)

6.55

Total Debt(mrq)

203.11M

Total Debt/Equity(mrq)

36.10%

Current Ratio(mrq)

3.38%

Quick Ratio(mrq)

3.38%

Book Value Per Share(mrq)

4.10

Cash Flow

Operating Cash Flow Per Share(ytd)

0.10

Free Cash Flow(ytd)

11.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement